Equities

Canopy Growth Corp

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Canopy Growth Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CAD)1.48
  • Today's Change0.05 / 3.50%
  • Shares traded1.62m
  • 1 Year change-44.78%
  • Beta2.4003
Data delayed at least 15 minutes, as of Feb 13 2026 21:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Canopy Growth Corporation is a Canada-based cannabis company. The principal activities of the Company are the production, distribution and sale of a diverse range of cannabis and cannabinoid-based products for both adult-use and medical purposes under a portfolio of distinct brands in Canada. The Company delivers innovative products from owned and licensed brands, including Tweed, 7ACRES, DOJA, Deep Space, and Claybourne, as well as category defining vaporization devices by Storz & Bickel. Its segments include Canada cannabis, and Storz & Bickel. Its Canada cannabis segment includes the production, distribution, and sale of a range of cannabis, hemp, and cannabis related products in Canada. Its Storz & Bickel segment includes the production, distribution, and sale of vaporizers. In addition, it serves medical cannabis patients globally with principal operations in Canada, Europe and Australia.

  • Revenue in CAD (TTM)278.39m
  • Net income in CAD-327.29m
  • Incorporated2009
  • Employees960.00
  • Location
    Canopy Growth Corp1 Hershey DrSMITHS FALLS K7A 0A8CanadaCAN
  • Phone+1 (613) 599-9600
  • Fax+1 (613) 599-0018
  • Websitehttps://www.canopygrowth.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
WEED:TOR since
announced
Transaction
value
MTL Cannabis CorpAnnounced15 Dec 202515 Dec 2025Announced-38.33%84.03m
Data delayed at least 15 minutes, as of Feb 13 2026 21:00 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Charlotte's Web Holdings Inc67.05m-29.53m167.79m112.00--13.27--2.50-0.1861-0.18610.42220.07910.48931.3936.51598,637.40-21.55-28.40-24.66-32.2044.2646.82-44.04-74.381.65-6.810.8408---21.36-12.09-25.42---23.86--
Auxly Cannabis Group Inc146.00m45.34m170.88m388.004.070.9773.051.170.03070.03070.10190.12790.54011.756.63376,275.8016.77-18.3522.80-23.0552.0026.3431.05-72.021.053.070.2767--21.0271.0663.27---40.74--
Biosyent Inc42.18m8.63m171.33m0.0019.964.2114.694.060.74790.74793.653.540.90451.648.01--18.5215.4921.8317.8477.4679.9820.4720.114.23--0.021915.5710.8910.3312.5410.72-39.09--
Aurora Cannabis Inc373.12m-88.26m276.17m1.10k--0.5149--0.7402-1.57-1.586.649.460.45451.527.96338,890.10-11.73---15.10--1.35---25.80--1.48--0.151--27.32--130.82------
Cipher Pharmaceuticals Inc68.16m23.64m369.12m61.0016.352.3911.165.420.89280.89282.576.120.33222.154.291,117,375.0011.5219.6313.0323.1774.3279.7434.6959.540.97665.740.10520.0057.668.24-43.3634.34127.59--
Spectral Medical Inc2.71m-41.69m380.33m29.00------140.60-0.1455-0.14560.0095-0.23750.3314.437.0393,275.86-510.19-135.57---711.8956.1655.19-1,541.33-581.020.1044-0.1904----43.05-4.430.7223---30.03--
Canopy Growth Corp278.39m-327.29m598.10m960.00--0.7189--2.15-1.85-1.841.162.060.24522.087.59289,988.50-28.83-30.76-31.54-33.9526.568.54-117.57-315.364.26-0.17610.2518---9.47-7.57-24.90---56.47--
Knight Therapeutics Inc413.85m-3.49m623.99m745.00--0.821612.011.51-0.0378-0.03784.127.690.41161.843.96555,498.00-0.34740.0976-0.40150.114342.4946.11-0.8440.3511.68--0.12170.0013.1350.90125.73-21.4860.58--
DRI Healthcare Trust192.69m-52.24m881.18m36.00--2.0217.714.57-0.9453-0.94533.457.930.2149--3.915,352,556.00-5.83---6.38-------27.11----1.820.5077--16.24---103.68------
Cronos Group Inc180.23m49.15m1.35bn626.0028.830.922819.177.490.12330.12330.4643.850.1121.575.56--3.51-8.993.81-9.7743.352.2231.36-159.1521.28--0.00--34.8237.71158.81-48.79-19.52--
Data as of Feb 13 2026. Currency figures normalised to Canopy Growth Corp's reporting currency: Canadian Dollar CAD

Institutional shareholders

9.60%Per cent of shares held by top holders
HolderShares% Held
Jane Street Capital LLCas of 31 Dec 20257.43m2.20%
Tidal Investments LLCas of 31 Dec 20256.75m1.99%
Susquehanna Financial Group LLLPas of 30 Sep 20253.88m1.15%
Citadel Securities LLCas of 30 Sep 20253.63m1.07%
Millennium Management LLCas of 30 Sep 20253.14m0.93%
Global X Investments Canada, Inc.as of 31 Dec 20252.19m0.65%
D. E. Shaw & Co. LPas of 30 Sep 20251.86m0.55%
Morgan Stanley & Co. LLCas of 31 Dec 20251.41m0.42%
Two Sigma Investments LPas of 30 Sep 20251.21m0.36%
Headlands Technologies LLCas of 31 Dec 2025987.81k0.29%
More ▼
Data from 30 Sep 2025 - 12 Feb 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.